SCHEMBL2623142

SCHEMBL2623142

O=c1[nH]c(NCc2ccccc2)nc2[nH]cnc12

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.52
PKM P14618 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
PDE9A O76083 1/20 0.50
PIM1 P11309 1/20 0.50
PNP P00491 1/20 0.50
RECQL P46063 1/20 0.50
MEN1 O00255 1/20 0.49
LMNA P02545 1/20 0.49
POLB P06746 1/20 0.49
HTT P42858 1/20 0.49
KMT2A Q03164 1/20 0.49
XDH P47989 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
TSHR P16473 1/20 0.48
TP53 P04637 1/20 0.48
RAB9A P51151 1/20 0.48
FABP4 P15090 1/20 0.47
TYMS P04818 2/20 0.46
IP6K1 Q92551 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18251 0.80 PNP (0.62) PNPXDH
SCHEMBL2623146 0.79 ALDH1A1 (0.54) L3MBTL1MEN1KMT2ASMN1; SMN2
SCHEMBL1394088 0.78 PNP (0.61) PNPXDH
SCHEMBL2623144 0.78 TK1 (0.47) PIM1
SCHEMBL10047094 0.78 XDH (0.40) PNPLMNAXDH
SCHEMBL5062459 0.78 XDH (0.46) PNPMEN1POLBHTTKMT2A
Cyanide SCHEMBL2694132 0.76 PNP (0.58) PNPLMNAXDHTSHR
SCHEMBL7658491 0.76 KDM4E (0.44) PNPMEN1KMT2A
SCHEMBL28472801 0.76 ROCK2 (0.47) L3MBTL1MEN1POLBKMT2ASMN1; SMN2
SCHEMBL21183279 0.75 XDH (0.44) PKMPIM1PNPLMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12569439-B2 Bottom-up assembly of synthetic extracellular vesicles MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2026-03-10 US claimed
EP-4684872-A1 DEVICE AND METHOD FOR WATER-IN-AIR GENERATION OF DROPLETS Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2026-01-28 EP claimed
CN-117835992-A Method for activating T cells PACT制药公司 2024-04-05 CN claimed
US-20240100096-A1 METHODS OF ACTIVATING T CELLS ADOC SSF, LLC (US) 2024-03-28 US claimed
US-20230181466-A1 BOTTOM-UP ASSEMBLY OF SYNTHETIC EXTRACELLULAR VESICLES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2023-06-15 US claimed
US-20230038598-A1 MICROFLUIDIC PRODUCTION OF BIOFUNCTIONALIZED GIANT UNILAMELLAR VESICLES FOR TARGETED CARGO DELIVERY MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2023-02-09 US claimed
CN-115379829-A Synthesizing extracellular vesicles by bottom-up assembly 马克斯·普朗克科学促进学会 2022-11-22 CN claimed
CN-115087434-A Microfluidic production of bio-functionalized giant unilamellar vesicles for targeted cargo delivery 马克斯·普朗克科学促进学会 2022-09-20 CN claimed
EP-4054532-A1 MICROFLUIDIC PRODUCTION OF BIOFUNCTIONALIZED GIANT UNILAMELLAR VESICLES FOR TARGETED CARGO DELIVERY Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2022-09-14 EP claimed
EP-4054533-A1 BOTTOM-UP ASSEMBLY OF SYNTHETIC EXTRACELLULAR VESICLES Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2022-09-14 EP claimed
WO-2021152115-A1 BOTTOM-UP ASSEMBLY OF SYNTHETIC EXTRACELLULAR VESICLES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2021-08-05 WO claimed
EP-3858332-A1 BOTTOM-UP ASSEMBLY OF SYNTHETIC EXTRACELLULAR VESICLES Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2021-08-04 EP claimed
WO-2021123399-A1 MICROFLUIDIC PRODUCTION OF BIOFUNCTIONALIZED GIANT UNILAMELLAR VESICLES FOR TARGETED CARGO DELIVERY MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2021-06-24 WO claimed
EP-3838266-A1 MICROFLUIDIC PRODUCTION OF BIOFUNCTIONALIZED GIANT UNILAMELLAR VESICLES FOR TARGETED INTRACELLULAR CARGO DELIVERY Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2021-06-23 EP claimed
US-12569439-B2 Bottom-up assembly of synthetic extracellular vesicles MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2026-03-10 US disclosed
EP-4684872-A1 DEVICE AND METHOD FOR WATER-IN-AIR GENERATION OF DROPLETS Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2026-01-28 EP disclosed
EP-4619524-A1 METHODS AND COMPOSITIONS FOR PREVENTING, TREATING, OR REVERSING CARDIAC DIASTOLIC DYSFUNCTION Genkardia Inc. (US) 2025-09-24 EP disclosed
US-20110262661-A1 Optical performance humidity dependency improving agent for cellulose acylate film FUJIFILM CORPORATION (JP) 2011-10-27 US disclosed
US-20110076423-A1 CELLULOSE ACYLATE FILM, RETARDATION FILM, POLARIZER AND LIQUID CRYSTAL DISPLAY DEVICE FUJIFILM CORPORATION (JP) 2011-03-31 US disclosed
US-20110076423-A1 CELLULOSE ACYLATE FILM, RETARDATION FILM, POLARIZER AND LIQUID CRYSTAL DISPLAY DEVICE FUJIFILM CORPORATION (JP) 2011-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230038598-A1 MICROFLUIDIC PRODUCTION OF BIOFUNCTIONALIZED GIANT UNILAMELLAR VESICLES FOR TARGETED CARGO DELIVERY PCNA, BOD1L1, SARS1 HPGD 3901/4885PKM 3244/4885L3MBTL1 113/4885
US-12569439-B2 Bottom-up assembly of synthetic extracellular vesicles EXOSC10, PLTP, EXOSC9 HPGD 4685/4885PKM 3200/4885L3MBTL1 3656/4885
US-20110262661-A1 Optical performance humidity dependency improving agent for cellulose acylate film ALKBH1, ACOT7, ALKBH2 HPGD 3788/4885PKM 3902/4885L3MBTL1 2374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.